For paralysis caused by severe spinal cord injury, millions of people around the world are affected by the disease
INFECTION: The level of plasma interferon-γ-inducible protein 10 (IP-10) in humans is correlated with the severity of extrapulmonary tuberculosis
Time of Update: 2021-09-28
The results of the study found that compared with healthy controls, patients with tuberculosis external pulmonary phenotypic disease had significantly increased plasma IP-10 levels (p <0.
Nancy Y. Ip's research group uses genome editing technology to explore the whole brain treatment of Alzheimer's disease
Time of Update: 2021-08-27
This effectively destroys the mutations caused by FAD in the AD mouse model and improves the AD pathology of the entire brain, paving the way for the development of new treatments for the disease .
The three details are well grasped, and the success rate of human iPS-liver differentiation is up up up!
Time of Update: 2021-08-17
Technical information: Next-generation human iPS cell-derived hepatocytes for metabolic disease modeling 4.
The first patient in the clinical trial of Guangshengtang hepatitis B treatment innovative drug GST-HG141 was enrolled
Time of Update: 2021-08-05
for administration . > GST-HG141 is a new class of anti-hepatitis B virus drug with a brand-new target. It is a hepatitis B core protein inhibitor that can inhibit
Blood | Using iPS cells in vitro hematopoietic cell differentiation system to study hereditary
Time of Update: 2021-05-22
gene into the patient’s iPS cells. This replenishment system can be used by doxycycline. (DOX) Induces the expression of ADH5. At the same time, the author made ADH5/ALDH2 knockout cells based
Science Sub-Journal: iPS Stem Cell Therapy Successfully Promotes the Recovery of Stroke and Dementia
Time of Update: 2021-05-09
progenitors repair functional deficits due to white matter stroke and vascular dementia in rodents in the Science Translational Medicine journal. Research papers. The research team used artificially induced
Guangshengtang: Innovative hepatitis B treatment drug GST-HG141 was approved for phase Ib clinical trials
Time of Update: 2021-04-24
hepatitis B treatment drug GST-HG141 issued by the Ethics Committee of the First Hospital of Jilin University, marking that the phase Ib clinical trial program has passed the review It is confirmed that the experiment has been allowed to enter the substantive development period. >
iPS cells are used for COVID-19 drug screening
Time of Update: 2021-04-16
From the screening of 500 drugs, 5 showed promise worthy of further research, including raloxifene (a drug used to treat breast cancer and osteoporosis ) and pioglitazone (a drug used to treat diabetes medicine).
New breakthroughs in iPS cell research allow the cultivation of three mini-organs at the same time
Time of Update: 2021-03-01
Researchers at Tokyo Medical and Dental University in Japan have teamed up with their U.S. counterparts to grow three mini-organs of the liver, bile tub and pancreas using human iPS cells at the same time.
Science Sub-Journal: Using neurons from iPS cells can be used to test treatments for Christiansen syndrome
Time of Update: 2021-02-27
study was published in the February 10, 2021 issue of the Journal of Science Translational Medicine under the title "Human neurons from Christianson syndrome ipsCs reveal mutation-specific responses to rescue strategies." images from Science Translational Medicine, 2021, doi:10.1126/scitranslmed.aaw0682.
Mr. Ip Yip, President of Ye's Chemical Enterprise Development, was awarded the 2018 Hong Kong Young Industrialist of the Year Award
Time of Update: 2020-12-10
Mr. Ip Yip, President of Enterprise Development of Ye Chemical Group, was awarded the 2018 Hong Kong Young Industrialist Award by the Federation of Hong Kong Industries.
The innovative HBsAg inhibitor GST-HG121 for hepatitis B treatment in Guangshengtang was approved clinically.
Time of Update: 2020-09-26
hepatitis B treatment innovative drug GST-HG121 is a hepatitis B surface antigen (HBsAg) inhibitor, is the company's hepatitis B clinical cure roadmap "peak plan" an important component.
"All-in-one Cells" for Regenerative Medicine: Introduction to the iPS Cell Research Institute, Kyoto University.
Time of Update: 2020-09-11
Induced cynic stem cells (iPS cells) have shown great potential in areas such as regenerative medicine since they were invented more than a decade ago by Kyoto University professor Tsahmi Yamano, and clinical studies have been successful.
Guangshengtang hepatitis B treatment of the global innovative drug HBsAg inhibitor GST-HG131 was approved by the Clinical Trial Ethics Committee.
Time of Update: 2020-08-18
GST-HG131 is the world's leading first-in-Class program and is expected to become the world's first globally listed hepatitis B HBsAg small molecule inhibitor innovation.
Complications occur after transplantation of retinal cells bred by allogeneic induced pluripotent stem cells (iPS cells).
Time of Update: 2020-08-14
similar transplants on four elderly macular degeneration patients. , however, the researchers admitted on the 16th of this month, one of the 70-year-old male patients had retinal edema, although no urgent treatment is required, but also no hope
The epigenetic characteristics of iPS cells, the source of chemical small molecules, are closer to ES cells.
Time of Update: 2020-08-11
that the epigenetic characteristics of iPS cells from the source of chemical small molecules are closer to the epigenetic characteristics of ES cells. embryonic stem cells (ES cells) have great potential for application in the clinical
Next year, the world's first clinical trial of iPS cells to treat heart disease will be conducted.
Time of Update: 2020-08-09
heart disease, the second clinical application of iPS cells, the journal Nature reported. team plans to conduct the world's first clinical trial of iPS cells to treat heart disease next year. the Ministry of Health, Labour and Welfare
IPS Cell Research Center at Kyoto University, Japan
Time of Update: 2020-07-04
In addition, Professor Zefang Shu, a professor at Osaka University who has restored the function of the patient's heart muscle with the patient's leg cells, will work with the above-mentioned center to study iPS cells.
